Table 1.
Patient characteristics of the full ConcertAI cohort and development and validation sub-cohorts
| Variables | Full cohort | Development sub-cohort | Validation sub-cohort |
|---|---|---|---|
| (n = 4666) | (n = 3225) | (n = 1441) | |
| Age at aNSCLC diagnosis, years, mean ± SD | 68.69 ± 8.50 | 68.68 ± 8.35 | 68.70 ± 8.80 |
| Gender, n (%) | |||
| Female | 2042 (43.77%) | 1404 (43.54%) | 638 (44.27%) |
| Male | 2624 (56.23%) | 1821 (56.46%) | 803 (55.73%) |
| Race, n (%) | |||
| White | 3797 (81.37%) | 2518 (78.08%) | 1279 (88.75%) |
| Non-White | 869 (18.63%) | 707 (21.92%) | 162 (11.24%) |
| Practice type, n (%) | |||
| Academic | 576 (12.34%) | 484 (15.01%) | 92 (6.38%) |
| Community | 4090 (87.66%) | 2471 (84.99%) | 1349 (93.62%) |
| Smoking status, n (%) | |||
| History of smoking | 4197 (89.95%) | 2890 (89.61%) | 1307 (90.70%) |
| No history of smoking | 412 (8.83%) | 296 (9.18%) | 116 (8.05%) |
| Stage at initial diagnosis of NSCLC, n (%) | |||
| Stage 1 | 440 (9.43%) | 289 (8.96%) | 151 (10.48%) |
| Stage 2 | 198 (4.24%) | 136 (4.21%) | 62 (4.30%) |
| Stage 3 | 541 (11.59%) | 370 (11.47%) | 171 (11.87%) |
| Stage 4 | 3487 (74.73%) | 2430 (75.35%) | 1057 (73.35%) |
| Treatment, n (%) | |||
| ICI only | 1712 (36.7%) | 1210 (37.5%) | 502 (34.8%) |
| ICI + chemotherapy | 2919 (62.6%) | 1988 (61.6%) | 931 (64.6%) |
| ICI + chemotherapy + other targeted agents (anti-HER2/anti-VEGF) | 35 (0.7%) | 27 (0.8%) | 8 (0.5%) |
| Outcome | |||
| Overall Survival days, mean ± SD | 479 ± 485 | 489 ± 494 | 459 ± 464 |
| Overall Survival days, median (Q1-Q3) | 314 (117, 684) | 320 (122, 696) | 299 (109, 654) |
| Observed events, n (%) | 3317 (71.09%) | 2,273 (70.48%) | 1044 (72.45%) |
NSCLC non-small cell lung cancer, aNSCLC advanced non-small cell lung cancer, SD standard deviation, ICI immune checkpoint inhibitor, HER2 human epidermal growth factor receptor-2, VEGF vascular endothelial growth factor.